ProCE Banner Activity

CASPIAN: 3-Yr Survival Update of First-line Durvalumab + Tremelimumab + EP vs Durvalumab + EP vs EP Alone in Extensive-Stage SCLC

Slideset Download
Conference Coverage

After a median follow-up of more than 3 years, this update showed sustained overall survival benefit with adding durvalumab to etoposide/platinum chemotherapy for the first-line treatment of patients with extensive-stage SCLC.

Released: September 23, 2021

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Exelixis, Inc.

Ipsen Biopharmaceuticals Inc